Examples of using Tasigna in English and their translations into Hungarian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Programming
-
Official/political
-
Computer
Tasigna is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia(CML) in the chronic phase.
Tasigna must not be taken in conjunction with food(see sections 4.2 and 4.5) and should be taken 2 hours after a meal.
Tasigna may need to be temporarily withheld and/or dose reduced for haematological toxicities(neutropenia, thrombocytopenia)
Tasigna can be used by people aged 65 years and over at the same dose as for other adults.
That Tasigna can cause prolongation of the QT interval
Tasigna is used when patients cannot tolerate other treatments including imatinib(another anticancer medicine),
Tasigna has been studied in two main studies involving a total of 439 patients with CML,
Children and adolescents Tasigna is not recommended for use in children
1% of patients receiving Tasigna.
Most responders achieved their MCyR rapidly within 3 months(median 2.8 months) of starting Tasigna treatment and these were sustained(median duration has not been reached).
Tasigna is used to treat a type of leukaemia called Philadelphia chromosome positive chronic myeloid leukaemia(Ph-positive CML).
Caution should be exercised when co-administering Tasigna with substrates of these enzymes that have a narrow therapeutic index e. g. astemizole,
How to take Tasigna• Swallow the capsules whole with water.•
Monitoring your Tasigna treatment You will have regular tests, including blood tests, during treatment.
Tasigna must not be used in people who are hypersensitive(allergic) to nilotinib or any of the other ingredients.
Non-haematological adverse reactions(excluding laboratory abnormalities) that are reported in at least 5% of the patients in Tasigna clinical studies are shown in Table 2.
How long to take Tasigna Continue taking Tasigna every day for as long as your doctor tells you.
in your body to see how Tasigna is tolerated.
Tasigna should not be used during pregnancy unless the clinical condition of the woman requires treatment with nilotinib.
Tasigna is a potent inhibitor of the Abl tyrosine kinase activity of the Bcr-Abl oncoprotein both in cell lines and in primary Philadelphia-chromosome positive leukaemia cells.